Startseite
Kongressberichte & Archiv
ESMO 2017 Congress
Late breaking news
LBA Press Conference: Melanoma cancer
Papers presented
Presenting Author - Jeffrey Weber: Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: a randomized, double-blind, phase 3 trial (CheckMate 238)
 |
MORE INFO |
ORIGINAL ARTICLE
J. Weber and Others
Also of Interest but not presented at the press conference:
ORIGINAL ARTICLE
J.D. Wolchok and Others
Presenting Author - Axel Hauschild: COMBI-AD: Adjuvant Dabrafenib (D) Plus Trametinib (T) for Resected Stage III BRAF V600E/K–Mutant Melanoma
|
MORE INFO |
ORIGINAL ARTICLE
G.V. Long and Others
Presenting Author - Karl Lewis: BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence